AOD-9604 vs GHRP-6
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
AOD-9604
AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191). It was developed to have the fat-reducing effects of growth hormone without the adverse effects on blood sugar or growth.
Full details →GHRP-6
Growth Hormone Releasing Peptide 6 (GHRP-6) is one of the first synthetic growth hormone secretagogues discovered. It stimulates significant GH release but is known for causing intense hunger.
Full details →Side-by-Side Comparison
| Aspect | AOD-9604 | GHRP-6 |
|---|---|---|
| Dose Range | 300 mcg–500 mcg | 100 mcg–300 mcg |
| Frequency | 1x daily | 3x daily |
| Cycle Length | 12–24 weeks | 8–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat accumulation) without affecting blood sugar or growth. Works specifically on adipose tissue through a mechanism independent of GH receptors. | Acts as a ghrelin mimetic, binding to the GHS-R receptor in the pituitary and hypothalamus. Stimulates GH release and also significantly increases appetite by mimicking ghrelin's hunger-signaling effects. |
| Typical Dosage | Research dosing typically ranges from 250-500mcg daily, often split into morning and afternoon doses. Some protocols use higher doses up to 1mg. | Typical dosing: 100-300mcg administered 2-3 times daily. Often combined with GHRH peptides like CJC-1295 for synergistic effects. |
| Administration | Subcutaneous injection, typically in the abdominal area. Best administered on an empty stomach. Can be combined with exercise for enhanced effects. | Subcutaneous injection. Best administered on an empty stomach. The strong hunger response can be beneficial for those trying to gain weight but challenging for cutting. |
| Side Effects | Generally well-tolerated. May cause headaches, injection site reactions, or temporary lethargy. Does not affect blood glucose like full GH. | Intense hunger (most notable effect), water retention, increased cortisol and prolactin, tingling/numbness, and potential blood pressure changes. |
| Best For |
Key Differences
Unique to AOD-9604:
Unique to GHRP-6:
Key Studies
AOD-9604
- AOD-9604 does not influence the WADA hGH isoform immunoassay.
Drug testing and analysis, 2013
- AOD-9604 Metabolic.
Current opinion in investigational drugs (London, England : 2000), 2004
GHRP-6
- Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation.
Journal of nanobiotechnology, 2025
- Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms.
Frontiers in pharmacology, 2024
- [D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle.
Molecular and cellular endocrinology, 2015
Ready to Learn More?
Looking for trusted sources?